Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Global Market Report 2025

Description

Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is an advanced form of immunotherapy that genetically engineers natural killer (NK) cells with chimeric antigen receptors (CARs) to target and destroy cancer cells more effectively. This therapy is applied in treating hematologic malignancies, solid tumors, and certain viral infections, offering advantages such as a lower risk of cytokine release syndrome (CRS), reduced potential for graft-versus-host disease (GvHD), and feasibility for allogeneic (off-the-shelf) use.

The primary types of CAR-NK cell therapy include cytokine therapy, adoptive NK cell therapy, genetically engineered NK cell therapy, and others. Cytokine therapy uses signaling proteins, such as interferons or interleukins, to modulate the immune system, either enhancing anti-tumor activity or suppressing harmful inflammation in autoimmune conditions. NK cells can be sourced from peripheral blood, cord blood, induced pluripotent stem cells (iPSCs), or established NK cell lines. Applications include treatment of solid tumors, hematologic malignancies, and more, with key end users comprising hospitals, cancer research institutes, and biotechnology and pharmaceutical companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market research report is one of a series of new reports from The Business Research Company that provides chimeric antigen receptor-natural killer (CAR-NK) cell therapy market statistics, including the chimeric antigen receptor-natural killer (CAR-NK) cell therapy industry global market size, regional shares, competitors with the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market share, detailed chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy industry. This chimeric antigen receptor-natural killer (CAR-NK) cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market size has grown strongly in recent years. It will grow from $2.27 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to the rising global incidence of cancer, growing emphasis on immunotherapy, early clinical successes of natural killer (NK) cell therapies, increased government funding for cancer research, and the expansion of cell therapy manufacturing infrastructure.

The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market size is expected to see strong growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing investments in cellular immunotherapy, expanding collaborations between biotechnology and pharmaceutical companies, rising demand for off-the-shelf cancer therapies, growth in clinical trials for chimeric antigen receptor-natural killer (CAR-NK) therapies, and greater adoption of precision oncology. Major trends during the forecast period include technological advancements in genetic engineering, innovations in chimeric antigen receptor (CAR) design, development of allogeneic natural killer (NK) cell platforms, research in tumor microenvironment modulation, and integration of artificial intelligence (AI) in cell therapy development.

The increasing global incidence of cancer is expected to drive the growth of the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market in the coming years. Cancer comprises a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can invade and damage body tissues. Factors such as aging populations and unhealthy lifestyles contribute to the rising cancer rates, as older age leads to accumulation of genetic mutations over time, while habits like smoking, poor diet, and physical inactivity increase cancer risk. CAR-NK cell therapy supports cancer treatment by engineering natural killer cells to precisely target and destroy cancer cells, enhancing the immune system's ability to attack tumors. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, estimated that the 20 million new cancer cases reported in 2022 are expected to increase by 77% to over 35 million cases by 2050. Thus, the rising global cancer incidence is fueling the growth of the CAR-NK cell therapy market.

Leading companies in the CAR-NK cell therapy market are developing advanced solutions, such as conditioning chemotherapy-free treatments, to create safer and more effective off-the-shelf cellular therapies. Conditioning chemotherapy-free treatment eliminates the need for intensive pre-treatment chemotherapy to suppress the patient's immune system before administering cellular therapies, thereby reducing toxicity and side effects. For instance, in November 2024, Fate Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, launched FT522, an off-the-shelf CD19-targeted CAR NK cell therapy. This therapy incorporates alloimmune defense receptor technology, allowing CAR NK cells to persist and selectively deplete pathogenic B cells in patients with relapsed or refractory B-cell lymphoma and autoimmune diseases, demonstrating promising safety and efficacy in early-phase clinical trials without requiring intense immune system suppression.

In August 2022, Gicell, a South Korea-based biotechnology company, partnered with HK Inno.N to jointly develop next-generation CAR-NK cell therapies. Through this collaboration, Gicell and HK Inno.N aim to leverage their expertise to advance the development, manufacturing, and commercialization of innovative allogeneic CAR-NK therapies for cancer treatment. HK Inno.N Corporation is a South Korea-based pharmaceutical company.

Major players in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market are Takeda Pharmaceutical Company Limited, Artiva Biotherapeutics Inc., Nkarta Inc., ImmunityBio Inc., Fate Therapeutics Inc., Acepodia Inc., PersonGen BioTherapeutics Inc., Cartherics Inc., Century Therapeutics Inc., Catamaran Bio Inc., Glycostem Therapeutics Ltd., ImmuneBridge Co. Ltd., ONK Therapeutics Inc., Senti Biosciences Inc., Wugen Therapeutics Inc., Chimeric Therapeutics Limited, East Ocyon Bio, Nuwacell Biotechnologies Co. Ltd., Nkarta Therapeutics Inc., and GICELL Co. Ltd.

North America was the largest region in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chimeric antigen receptor-natural killer (CAR-NK) cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market includes revenues earned by entities through the research and development, clinical trial management, cell manufacturing, personalized treatment planning, and post-therapy patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chimeric antigen receptor-natural killer (car-nk) cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chimeric antigen receptor-natural killer (car-nk) cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chimeric antigen receptor-natural killer (car-nk) cell therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Cytokine Therapy; Adoptive Natural Killer (NK) Cell Therapy; Genetically Engineered Natural Killer Cell Therapy; Other Types
2) By Cell Source: Peripheral Blood-Derived Natural Killer Cells; Cord Blood-Derived Natural Killer Cells; Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells; Natural Killer Cell Lines
3) By Application: Solid Tumors; Hematological Malignancies; Other Applications
4) By End User: Hospitals; Cancer Research Institutes; Biotechnology And Pharmaceutical Companies
Subsegments:
1) By Cytokine Therapy: Interleukin Therapy; Interferon Therapy; Colony Stimulating Factor Therapy; Tumor Necrosis Factor Therapy
2) By Adoptive Natural Killer Cell Therapy: Autologous Natural Killer Cell Therapy; Allogeneic Natural Killer Cell Therapy; Expanded Natural Killer Cell Therapy; Activated Natural Killer Cell Therapy
3) By Genetically Engineered Natural Killer Cell Therapy: Chimeric Antigen Receptor Natural Killer Cell Therapy; T Cell Receptor Engineered Natural Killer Cell Therapy; Gene Edited Natural Killer Cell Therapy; Cytokine Gene Modified Natural Killer Cell Therapy
4) By Other Types: Combination Therapy; Immune Checkpoint Inhibitor Therapy; Antibody Dependent Cellular Cytotoxicity Therapy; Oncolytic Virus Therapy
Companies Mentioned: Takeda Pharmaceutical Company Limited; Artiva Biotherapeutics Inc.; Nkarta Inc.; ImmunityBio Inc.; Fate Therapeutics Inc.; Acepodia Inc.; PersonGen BioTherapeutics Inc.; Cartherics Inc.; Century Therapeutics Inc.; Catamaran Bio Inc.; Glycostem Therapeutics Ltd.; ImmuneBridge Co. Ltd.; ONK Therapeutics Inc.; Senti Biosciences Inc.; Wugen Therapeutics Inc.; Chimeric Therapeutics Limited; East Ocyon Bio; Nuwacell Biotechnologies Co. Ltd.; Nkarta Therapeutics Inc.; GICELL Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37725

1. Executive Summary

2. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Characteristics

3. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Trends And Strategies

4. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Growth Analysis And Strategic Analysis Framework

5.1. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Growth Rate Analysis
5.4. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Total Addressable Market (TAM)

6. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Segmentation

6.1. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cytokine Therapy
Adoptive Natural Killer (NK) Cell Therapy
Genetically Engineered Natural Killer Cell Therapy
Other Types
6.2. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peripheral Blood-Derived Natural Killer Cells
Cord Blood-Derived Natural Killer Cells
Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells
Natural Killer Cell Lines
6.3. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Solid Tumors
Hematological Malignancies
Other Applications
6.4. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Research Institutes
Biotechnology And Pharmaceutical Companies
6.5. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Sub-Segmentation Of Cytokine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interleukin Therapy
Interferon Therapy
Colony Stimulating Factor Therapy
Tumor Necrosis Factor Therapy
6.6. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Sub-Segmentation Of Adoptive Natural Killer Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autologous Natural Killer Cell Therapy
Allogeneic Natural Killer Cell Therapy
Expanded Natural Killer Cell Therapy
Activated Natural Killer Cell Therapy
6.7. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Sub-Segmentation Of Genetically Engineered Natural Killer Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chimeric Antigen Receptor Natural Killer Cell Therapy
T Cell Receptor Engineered Natural Killer Cell Therapy
Gene Edited Natural Killer Cell Therapy
Cytokine Gene Modified Natural Killer Cell Therapy
6.8. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Combination Therapy
Immune Checkpoint Inhibitor Therapy
Antibody Dependent Cellular Cytotoxicity Therapy
Oncolytic Virus Therapy

7. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Regional And Country Analysis

7.1. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

8.1. Asia-Pacific Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

9.1. China Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
9.2. China Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

10.1. India Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

11.1. Japan Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
11.2. Japan Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

12.1. Australia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

13.1. Indonesia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

14.1. South Korea Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
14.2. South Korea Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

15.1. Western Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
15.2. Western Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

16.1. UK Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

17.1. Germany Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

18.1. France Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

19.1. Italy Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

20.1. Spain Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

21.1. Eastern Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
21.2. Eastern Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

22.1. Russia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

23.1. North America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
23.2. North America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

24.1. USA Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
24.2. USA Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

25.1. Canada Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
25.2. Canada Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

26.1. South America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
26.2. South America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

27.1. Brazil Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

28.1. Middle East Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
28.2. Middle East Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

29.1. Africa Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview
29.2. Africa Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Cell Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Competitive Landscape And Company Profiles

30.1. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Competitive Landscape
30.2. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Company Profiles
- 30.2.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Artiva Biotherapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Nkarta Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. ImmunityBio Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Fate Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Other Major And Innovative Companies

31.1. Acepodia Inc.
31.2. PersonGen BioTherapeutics Inc.
31.3. Cartherics Inc.
31.4. Century Therapeutics Inc.
31.5. Catamaran Bio Inc.
31.6. Glycostem Therapeutics Ltd.
31.7. ImmuneBridge Co. Ltd.
31.8. ONK Therapeutics Inc.
31.9. Senti Biosciences Inc.
31.10. Wugen Therapeutics Inc.
31.11. Chimeric Therapeutics Limited
31.12. East Ocyon Bio
31.13. Nuwacell Biotechnologies Co. Ltd.
31.14. Nkarta Therapeutics Inc.
31.15. GICELL Co. Ltd.

32. Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

34. Recent Developments In The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

35. Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market High Potential Countries, Segments and Strategies

35.1 Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market In 2029 - Countries Offering Most New Opportunities
35.2 Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market In 2029 - Segments Offering Most New Opportunities
35.3 Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer